

FOSUN

TOWARDS A BRIGHTER LIFE



X



Facebook



YouTube



WeChat



Weibo



Douyin(Tik Tok)

HONG KONG, CHINA

Address : Room 808, Icbc Tower, 3 Garden Road, Central
Tel : +852 2509 3228
Fax : +852 2509 9028

SHANGHAI, CHINA

Address : Building S1, Bund Finance Center, No. 600, Zhongshan East 2nd Road, Huangpu District
Tel : +86 21 2315 6666
Fax : +86 21 6130 3288
Postcode : 200010

BEIJING, CHINA

Address : Fosun International Center, No. 237, Chaoyang North Road, Chaoyang District, Beijing
Tel : +86 10 59152299

NEW YORK, USA

Address : 28 Liberty Street, 44th Floor, New York, NY 10005, USA
Tel : +1 646 553 5892

LISBON, PORTUGAL

Address : Largo Do Chiado 8, 1249-125 Lisbon, Portugal
Tel : +351 213 401 500

LONDON, UK

Address : Units 18 & 19, Part First Floor, The Royal Exchange, London EC3V 3LN
Email : londonoffice@fosun.com



FOSUN 复星

Rooted in China, Creating a Global Happiness Ecosystem
Fulfilling the Needs of Families Worldwide in Health, Happiness and Wealth

CONTENTS

02 | About Fosun

10 | Business Overview

22 | Fosun's Strategy

34 | Our Pursuit

FOSUN TOWARDS A BRIGHTER LIFE

MISSION

Creating happier lives
for families worldwide

VISION

Rooted in China, Fosun is committed to creating
a global happiness ecosystem fulfilling the needs of
families worldwide in Health, Happiness and Wealth

VALUE

Self-improvement, Teamwork, Performance,
and Contribution to Society



A GLOBAL INNOVATION-DRIVEN CONSUMER GROUP

ABOUT FOSUN

Fosun was founded in 1992. Our mission is to provide high-quality products and services for families around the world in Health, Happiness, Wealth, and Intelligent Manufacturing segments

Total Revenue → **198.2** billion RMB

Total Assets → **808.4** billion RMB

Number of Employees → **100,000+**

Outlook from S&P Global Ratings → **Stable**

MSCI ESG Rating → **AA**

Global Operations → **35+** countries and regions

R&D Investment → **7.4** billion RMB **10+** Global technology innovation centers

Industrial Operation Profit¹ → **4.9** billion RMB

¹ Industrial Operation Profit includes the profit contribution from operation subsidiaries, associates and joint ventures which are under equity method accounting

ABOUT FOSUN

ROOTED IN CHINA DEVELOPING GLOBALLY

Over the past 30 years, Fosun has implemented the twin-driver strategy of "Profound Industry Operations + Industrial Investment" to strengthen its foothold in various industries. Through continuous innovation, Fosun has achieved rapid development by capitalizing on the opportunities and momentum of China and the world's economic development

1992
Fosun was founded with a capital of RMB 38,000

1994
Fosun Pharma Forte

2002
Yuyuan Inc.

2003
Sinopharm Group

2007
Hainan Mining
Fosun International(00656.HK) was listed on HKEX

2010
Club Med
Henlius

2011
BFC

2012
Pramerica Fosun Life Insurance
Peak Re
Starcastle Senior Living

2013
Atlantis Sanya
Foshan Fosun Chancheng Hospital
Sisram Med

2014
Fidelidade
Luz Saúde
Roc Oil

2015
Privatization of Club Med
Thomas Cook
Silver Cross

2016
Gland Pharma
HAL
Wolverhampton Wanderers
AHAVA

2017
Fosun United Health Insurance
Intuitive Fosun
Fosun Kite

2018
LANVIN
Wolford
Lovelink
Songhelou
Fosun Tourism Group was listed on HKEX

2019
FFT
Henlius was listed on HKEX

2020
DJULA
WEI
Shede Spirits

2021
Sergio Rossi
Bankhaus Lampe
Wansheng

2022
Lanvin Group was listed on NYSE
Yelanggujiu

2023
Overseas debut of Yuyuan Garden Lantern Festival

LEADERSHIP



Guo Guangchang

Executive Director
Chairman of the Company

Aged 56, is an Executive Director and Chairman of the Company and the founder of the Group. As of 31 December 2023, Mr. Guo was also a director of both Fosun Holdings and Fosun International Holdings (the direct and indirect controlling shareholders of the Company, respectively), and an honorary chairman of the Zhejiang Chamber of Commerce, Shanghai, and etc. Mr. Guo has been awarded the title of "China Democratic League Anti-COVID-19 Outstanding Individual", the "Anti-epidemic Action Award" at the 2020 Ram Charan Management Practice Awards issued by Harvard Business Review (Chinese edition), the "Outstanding Businessman of Listed Company Award" at the Top 100 Hong Kong Listed Companies Awards, co-organized by Tencent News and Finet Group Limited, the "Lifetime Achievement Award" at the 16th CNBC Asia Business Leaders Awards Ceremony, the "China's Top 50 Most Influential Business Leaders in 2023" by Fortune China, and etc. Mr. Guo received a bachelor's degree in philosophy in 1989 and a master's degree in business administration in 1999, both from Fudan University.

Wang Qunbin

Executive Director
Co-Chairman of the Company

Aged 54, is an Executive Director and Co-Chairman of the Company, and the founder of the Group. Mr. Wang has been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange) and Sinopharm (listed on the Hong Kong Stock Exchange). Mr. Wang has been awarded the "Asia Pacific Outstanding Entrepreneur Award" by Enterprise Asia and the "Asian Corporate Director Recognition Award" at the Asian Excellence Awards by Corporate Governance Asia, and etc., and has been named one of the "Top 50 Ranking of China's Business Leaders" by Harvard Business Review. Mr. Wang received a bachelor's degree in Genetic Engineering from Fudan University in 1991.

Chen Qiyu

Executive Director
Co-CEO of the Company

Aged 51, is an Executive Director and Co-CEO of the Company. Mr. Chen joined the Group in 1994 and as of 31 December 2023, he was also a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange) and Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange), a director of Gland Pharma (listed on the BSE Limited and National Stock Exchange of India Limited). As of 31 December 2023, Mr. Chen was the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceuticals Industry Association, and a member of the 14th Shanghai Standing Committee of the Chinese People's Political Consultative Conference, and etc. Mr. Chen has been awarded "Asia's Best CEO" by Corporate Governance Asia, and etc. Mr. Chen received a bachelor's degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.

Xu Xiaoliang

Executive Director
Co-CEO of the Company

Aged 50, is an Executive Director and Co-CEO of Fosun International. Mr. Xu joined the Group in 1998. As of 31 December 2023, Mr. Xu was a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and Shanghai Stock Exchange), an executive director and chairman of Fosun Tourism Group (listed on the Hong Kong Stock Exchange), a director of Yuyuan (listed on the Shanghai Stock Exchange), and various companies within the Group. As of 31 December 2023, Mr. Xu was a deputy to the 16th Shanghai Municipal People's Congress and the chairman of Shanghai International Fashion Federation. Mr. Xu has been awarded "Asia's Best CEO" by Corporate Governance Asia, the "Shanghai May Forth Youth Medal" and "Shanghai Top Ten Youth Businessmen", and etc. Mr. Xu received a master's degree in business administration from the East China Normal University in 2002 and received an EMBA degree from Fudan University in 2019.

Gong Ping

Executive Director
Executive President and
CFO of the Company

Aged 48, is an Executive Director, Executive President and CFO of the Company. Mr. Gong joined the Group in 2011 and as of 31 December 2023, he was also a director of Yuyuan (listed on the Shanghai Stock Exchange, resigned in January 2024) and various companies within the Group. He has been a senior assistant to president of the Group, the general manager of Corporate Development Department and the CEO of Fosun Hive. Prior to joining the Group, Mr. Gong worked at the Pudong branch and the headquarters of Bank of Shanghai as well as the PRC headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. As of 31 December 2023, Mr. Gong was a council member of Shanghai Association for Youth Entrepreneurship and Employment. Mr. Gong received a bachelor's degree in international finance from Fudan University in 1998, and obtained a master's degree in finance from Fudan University in 2005. Mr. Gong also received a master's degree in business administration from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.

Huang Zhen

Executive Director
Executive President and
CGO of the Company

Aged 52, is an Executive Director, Executive President and CGO of the Company. Mr. Huang joined the Group in 2017 and as of 31 December 2023, he was also the chairman of Yuyuan (listed on the Shanghai Stock Exchange) and Lanvin Group (listed on the New York Stock Exchange), and a director of Shede Spirits (listed on the Shanghai Stock Exchange), Resource Property (delisted from the National Equities Exchange and Quotations in December 2020), Shanghai Ballian (listed on the Shanghai Stock Exchange) and Sanyuan Foods (listed on the Shanghai Stock Exchange) and Fosun Tourism Group (listed on the Hong Kong Stock Exchange) and various companies within the Group. Before joining the Group, Mr. Huang was the deputy general manager of Shanghai Jahwa United Co., Ltd., and the general manager of Shanghai Herborist Cosmetics Co., Ltd., and etc. As of 31 December 2023, Mr. Huang was a member of the 14th Shanghai Standing Committee of the Chinese People's Political Consultative Conference and the 3rd Shanghai Huangpu District Standing Committee of the Chinese People's Political Consultative Conference, the chairman of Shanghai Huangpu District Federation of Industry and Commerce, the president of Shanghai Huangpu District Chamber of Commerce, the vice chairman of China Gold Association and Gems & Jewelry Trade Association of China, and etc. Mr. Huang has been awarded "Top Ten Economic Figures in China's Circulation Industry", "National Outstanding Commercial Entrepreneur", and etc. Mr. Huang received a bachelor's degree in economics from Shanghai University of Finance and Economics in 1994 and an MBA degree from Webster University (USA) in 1998.


Pan Donghui

Executive Director
Executive President and
CHO of the Company

Aged 54, is currently an Executive Director, Executive President and CHO of the Company. Mr. Pan was appointed as an executive director of the Company in March 2023. Mr. Pan joined the Group in 1994 and as of 31 December 2023, Mr. Pan was a non-executive director of Fosun Pharma (listed on the Shanghai Stock Exchange) and Fosun Tourism Group (listed on the Hong Kong Stock Exchange) and a director of Shanghai Foyo Culture & Entertainment Co., Ltd. (delisted from the National Equities Exchange and Quotations in April 2021). Mr. Pan has also served as a director of Shanghai Ganglian E-Commerce Holdings Co., Ltd. (listed on the Shenzhen Stock Exchange). Mr. Pan obtained a bachelor's degree in engineering from Shanghai Jiaotong University in China in 1991, and a master's degree in business administration from the University of Southern California in the United States in 2009.

GLOBAL BUSINESS FOOTPRINTS

• HEALTH • HAPPINESS • WEALTH • INTELLIGENT MANUFACTURING



FOSUN FAMILY CONSUMPTION ECOSYSTEM

As a global innovation-driven consumer group, FOSUN is dedicated to creating a global ecosystem fulfilling the needs of families in Health, Happiness and Wealth

BUSINESS OVERVIEW

FOSUN FAMILY CONSUMPTION ECOSYSTEM

HEALTH




HAPPINESS



WEALTH



INTELLIGENT MANUFACTURING



HEALTH

Transform the industry with technology to create healthier lives
Driven by technology innovation, the Health segment focuses on the three major areas of pharmaceutical, devices and diagnosis, and healthcare services and products

PHARMACEUTICALS

Fosun Pharma continues to promote innovative transformation, with revenue from innovative products maintaining rapid growth



RMB 5.937 billion

Fosun Pharma's R&D investment in 2023

Over 70

Pipeline projects mainly on innovation drugs and biosimilars (based on indications)

MEDICAL DEVICES & DIAGNOSTICS

Focusing on the operation of the medical device industry, Fosun Medtech is committed to becoming an industrial technology platform providing comprehensive digital and intelligent solutions



RMB 5.0 billion


Fosun Pharma's subsidiary, Fosun Health Capital, won the bid to manage the first batch of "20+8" industry funds in Shenzhen, exclusively managing a RMB 5.0 billion biopharmaceutical industry fund

HANSIZHUANG (serplulimab injection)

Independently developed by Fosun is the world's first monoclonal antibody drug targeting PD-1 approved for the first-line treatment of small cell lung cancer. Approved for four indications in the Chinese mainland
The first China-produced anti-PD-1 monoclonal antibody approved for marketing in Southeast Asia

Focusing on the in vitro diagnostics industry, Fosun Diagnostics is committed to becoming the world's leading technological innovator in medical diagnostic solutions

FOSUN DIAGNOSTICS (复星诊断)



In May 2023, Fosun Diagnostics launched the sophisticated, comprehensive, intelligent, agile F-A7000 Series assembly line system

5 R&D and Production Bases
Shanghai, Changsha, Taizhou, Hefei and Baidao, Suzhou

HANQUYOU (trastuzumab injection)

The first China-developed monoclonal antibody biosimilar approved in China, Europe, and U.S.
Launched in more than 40 countries and regions

Yi Kai Da (ejilunsai injection)

The first CAR-T cell therapy product approved for marketing in China
Second-line indication approved in Chinese Mainland
Benefited more than 600 lymphoma patients in China since its launch

Artesun® & Argesun® (artesunate for injection)

Treated more than 68 million severe malaria patients
The second generation, Argesun® became the world's first artesunate injectable presented with a single solvent system that received WHO Prequalification (WHO PQ)

Domestically-produced da Vinci Xi Surgical System

Approved for launch by NMPA in June 2023
The first domestically-produced da Vinci Xi Surgical System was officially put into use, achieving the localization and commercialization of the system

HEALTHCARE SERVICES

Based on its advantageous medical resources and digital platform, Fosun provides users with closed-loop solutions throughout the treatment course and one-stop health management services that combines healthcare, medicines, health and insurance

FOSUN HEALTH (复星健康)



LUZ SAÚDE



Focused ultrasound

Collaborated with Insightec to establish a JV Fosun-Insightec and commenced the commercialization, clinical application and R&D of focused brain ultrasound platform in the Chinese market

Ion Bronchial Navigation Operation Control System (Ion System)

Approved by NMPA

New markets

Sisram launched two products, Soprano Titanium and Alma Opus to new markets
Breas completed domestic manufacturing conversion and upgrading of various ventilators

6,548 beds¹

Approved beds in the controlled medical institutions under Fosun Health

¹ Bed count sourced from controlled subsidiaries, excluding Jianjia Healthcare, as of 31 December 2023

HAPPINESS

Focus on family customers

Centering on the happiness needs of global family customers, the Happiness segment establishes a strong presence in the two major areas of brand consumption and tourism and leisure

YUYUAN INC.

As one of the flagship platforms of Fosun's Happiness segment, Yuyuan owns 19 Chinese time-honored brands and several other leading brands, taking oriental lifestyle aesthetics as the key strategy to promote Chinese culture

Jewelry and Fashion



Food and Beverage



Chinese Watches




Liquor

Beauty & Health







FOSUN TOURISM GROUP

Fosun Tourism Group (FTG) is a world-leading leisure-focused integrated tourism group. With a mission of "Better Holiday, Better Life", FTG endeavors to pioneer holiday lifestyle and create a world-leading family leisure and tourism ecosystem



LANVIN GROUP

Lanvin Group, China's first global luxury goods group listed on the New York Stock Exchange (NYSE)



MORE HAPPINESS

Focusing on sports, e-sports, film and television and other content to create a diversified entertainment experience of Fosun



19

Yuyuan owns 19 Chinese time-honored brands

Yuyuan Garden Lantern Festival

In 2024, the Yuyuan Garden Lantern Festival in Shanghai continued the theme of "The Adventure of Mountains and Seas" and attracted more than 4 million visitors

In 2023, Yuyuan Garden Lantern Festival was held overseas for the first time. The Festival Dragons et Lanernes attracted nearly 200,000 local visitors in Paris, France

Club Med Urban Oasis

Launched new urban resort product line, Club Med Urban Oasis, leading the development of domestic urban vacations

1 hour

Offering various themed experiences and tourism features with the theme around the "Alps"

Only 1 hour drive from downtown Shanghai

10 Championships

Wolves' e-sports teams won 10 championships across various e-sports events in 2023. Honor of Kings team and Speed Drifters team have clinched nine and ten championships, respectively

5,016 stores

Yuyuan Jewelry & Fashion Group continues to accelerate store expansion, with the number of stores reaching 5,016

68 resorts

Club Med operates 68 resorts around the world, including 25 ice and snow resorts

82%

Sanya Atlantis had an average occupancy rate of 82% in 2023

One of the founding members of the English Football League

Wolverhampton Wanderers Football Club is the only team to have won championships in five different levels of English football league and has won 11 league titles, 4 FA Cups and 2 League Cups

WEALTH

Insurance + financial resources and asset management capabilities empower each other to create a closed-loop wealth ecosystem

INSURANCE

Establish a global presence and adhere to innovative development and insurance ecosystem development



RMB 60.6 billion


Insurance Premium

RMB 179.3 billion

Assets under management (Insurance)

INVESTMENT MANAGEMENT

Industrial investment + financial investment as twin-driver to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every stage of life



29.6%

Fosun Insurance Portugal's market share in Portugal

EUR 1.7 billion

Gross written premium from Fosun Insurance Portugal's international business

HIVE

Introduce industries to cities to facilitate urban development, creating a global urban hive benchmark



1.6 million

Registered users of MyFidelidade APP

Approx. RMB 2,288.5 billion

Assets under management (Investment)¹

¹Under group empowerment method, including assets directly held by Fosun International and its subsidiaries, and managed by third parties

RMB 323.3 billion


Domestic property assets under Fosun Hive's management

USD 13.8 billion

Overseas assets under Fosun Hive's management

INTELLIGENT MANUFACTURING

Develop digital intelligent technology globally to empower industrial manufacturing



Bougouni lithium mine

Hainan Mining obtained the controlling equity interest in the lithium mine of Bougouni in Mali, completing the upstream industrial chain integration of the new energy sector

70%

Easun Technology recorded a significant increase in its overseas orders, new orders from the North America increased by 70%

Advanced materials R&D

Wansheng newly established the Advanced Materials and Engineering Research Institute

FOSUN'S STRATEGY

FOSUN'S STRATEGY

FOCUSED STRATEGY WITH STEADY DEVELOPMENT: FOUR CORE COMPETENCIES TO DRIVE CORPORATE GROWTH



PROFOUND GLOBAL OPERATIONS

- Global presence
- Global business
- Global innovation
- Global talent



INNOVATION-DRIVEN

- Driven by product innovation
- Driven by digital intelligence innovation
- Driven by management innovation



FC2M¹ ECOSYSTEM


- Improve C2M capabilities
- Form ecosystem and achieve multiplier growth
- Enhance industrial capabilities through comprehensive digital intelligence to connect all ecosystems

¹FC2M: "F" represents Fosun and family, and C2M represents Client to Maker





Fosun Entrepreneurship / Ecosystem System

- Provide systematic methodology, tools and processes to realize Fosun's globalization, technological innovation and ecosystem operations
- Improve operational capabilities to create a sustainable operational system



PROFOUND GLOBAL OPERATIONS



Fosun Insurance Portugal

Rapid growth in international business, proportion of its international business increased to nearly 30%, mainly attributed to the increase from business in Latin America

Bougouni lithium mine

Hainan Mining obtained the controlling equity interest in the lithium mine of Bougouni in Mali, completing the upstream industrial chain integration of the new energy sector

Yuyuan Garden Lantern Festival

Yuyuan Garden Lantern Festival was held overseas for the first time in Paris

HANSIZHUANG (serplulimab injection)

The first home-made anti-PD-1 mAb approved for marketing in Southeast Asian countries

Easun Technology

Easun Technology recorded a significant increase in its overseas orders, new orders from the North America increased by 70%

Gland Pharma

Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO

Club Med

Operating 68 resorts around the world, including 25 ice and snow resorts
Launched new urban resort product line, Club Med Urban Oasis, leading the development of domestic urban vacations

HANQUYOU (trastuzumab injection)

Sales and marketing in more than 40 countries & regions globally

INNOVATION-DRIVEN

R&D investment in 2023

7.4 billion
Strengthen technology
innovation capability
(RMB)

10+
Global technology
innovation centers

INNOVATIVE TECHNOLOGY INNOVATION CENTERS IN VARIOUS FIELDS

- | | |
|--|--|
| Fosun Pharma Global R&D Center (national level) | Wansheng Technology Center (national level) |
| Fosun Pharma North America R&D Headquarters | Sichuan Engineering Technology Center for Intelligent
Brewing of Baiju |
| Fosun Pharma Academician Expert Workstation | Tianjin Seagull High-Precision Mechanical Watch
Enterprise Key Laboratory |
| Jiangsu Wanbang Recombinant Protein Drug Engineering Center | Fosun Cosmetics Global Innovation Center (CNAS certified) |
| Jiangsu Wanbang Engineering Research Center for Diabetic Drugs | Yuyuan Foods & Dining Group Innovation Center |
| Chongqing Yao Pharma National-Local Joint Research Center for
Lyophilized Preparations | Fosun Wine & Spirits Global Innovation Center |
| Chongqing Pharmaceutical Research Institute | Yuyuan Jewelry Creative House |
| Liaoning AVANC Pharma Professional Technology Innovation Center for
Tumor and Perioperative Drugs | Lanvin Group Fabric Innovation Center |
| Foshan Fosun Chancheng Hospital Tumor Precision Key Laboratory | Easun Technology Global R&D Center |
| Shanghai Henlius Global Innovation Center | |

HANSIZHUANG



The self-developed and world's first monoclonal antibody drug targeting PD-1 for first-line treatment of extensive stage small cell lung cancer
Approved for four indications in Chinese Mainland
The first home-made anti-PD-1 mAb approved for marketing in Southeast Asian countries

HANQUYOU



The first monoclonal antibody biosimilar approved in China, Europe and U.S.
Sales and marketing in more than 40 countries & regions globally

YI KAI DA



The first CAR-T cell therapy product approved for marketing in Chinese Mainland
Second-line indication approved in Chinese Mainland

Domestic da Vinci Xi surgical system



The first home-made da Vinci Xi surgical robot was officially put into use
Successfully launched and commenced the localization and commercialization of da Vinci Xi surgical system

Artesun® & Argesun®



Treated more than 68 million severe malaria patients
The second generation, Argesun®: the world's first artesunate injectable presented with a single solvent system that received WHO PQ

Remote medical service



Nearly 2 million remote medical service consultations by Fidelidade were recorded

Quantitative analysis of prepared dishes



Yuyuan Foods & Dining Group Innovation Center has been committed to the quantitative analysis technology of prepared dishes, leading the development of the first product standards in the prepared noodle industry

Precise and intelligent matching system of the vehicle body



Easun Technology's self-developed 2.5D advanced sensor significantly improves transmission speed and response time through industry-academia-research collaboration

Henlius

FC2M ECOSYSTEM

F C 2 M

Family	Client	Supply Chain	Product
Diverse Structure	Systematic Membership	Flexibility and Resilience	Innovative R&D High Gross Margin

Comprehensive Digital Supply-Chain & Intelligent Operations



FES SYSTEM

FES

Fosun Entrepreneurship / Ecosystem System



Certification and implementation of FES tools

100+ FES tools in the 3-year plan
51 FES tools completed

Expert-certified mechanism

Over 700 experts certified per year in the 3-year plan
1,116 experts certified

FESL¹ Certification

¹ FES leader & the head of FES

Cover 200+ enterprises in the 3-year plan
Appointed 79 FES Leaders covering 61 enterprises of the Group

Improvement projects

Over 40 projects per year in the 3-year plan
1,088 improvement projects

FOCUS ON KEY TALENT TO BUILD A TEAM WITH ENTREPRENEURIAL SPIRIT

Talents, the most valuable asset of Fosun

A robust team of talents determines the scalability of the company's future development

Consolidate the multi-level partner mechanism to form an elite partner echelon and lead key talent to manage the system

ELITE MANAGEMENT TEAM

150+ global partners
470+ industry partners
470+ functional line partners
60+ innovation partners

GLOCAL

20+ overseas global partners coming from countries including Portugal, France, Germany, the U.K., Japan, India, and the U.S.

TALENT DEVELOPMENT STRATEGY

Attract talents with development, appraise talents based on performance, train talents through works, and unite talents with career opportunities



FOSUN GLOBAL PARTNERS

300+

Future Fosun global partners



MID-LEVEL ENTREPRENEURS

3,000+

Future entrepreneur backups



FUTURE ENTREPRENEURS

30%

High-potential talents



TECHNOLOGY INNOVATION TALENTS

100+

Top scientists of Fosun ecosystem



SHARING HAPPINESS

OUR PURSUIT

REMARKABLE ESG ACHIEVEMENTS FOR A BRIGHTER LIFE



The only conglomerate in Greater China with an MSCI ESG rating of AA; with AA rating for 3 consecutive years
Selected as a constituent of the MSCI CHINA ESG LEADERS 10-40 Index
Its member company, Fosun Tourism Group's MSCI ESG rating jumped to AAA



In 2023, the rating in the Hang Seng Sustainability Index was improved to AA-
Selected as a constituent of Hang Seng Corporate Sustainability Index (Top 30) for the first time
Selected as a constituent of the Hang Seng ESG 50 Index for 3 consecutive years
Selected as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index for 4 consecutive years



In 2023, Fosun International's S&P Global Corporate Sustainability Assessment (CSA) score rose to 68 points, ranking among the top 6% of its peers around the world.
Included in S&P Global's Sustainability Yearbook 2024 and recognized as an "Industry Mover" by S&P Global for the first time



Scored FTSE ESG rating of 3.8 points and maintained its inclusion in the FTSE4Good Index Series

ESG RATINGS CONTINUED TO IMPROVE IN 2023

E



CARBON NEUTRALITY STRATEGY

Strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050

EHS management framework

Climate risk response

S



FOSUN FOR GOOD

Rural Doctors Program

Assist WHO in building a malaria-free world

Employee care

G



CORPORATE GOVERNANCE

Continue to optimize and evolve corporate risk management

Improve ESG governance structure

Proactive two-way communication

Better information disclosure based on GRI standards and TCFD framework

FOSUN FOR GOOD



The Fosun Foundation was established in November 2012 as the main humanitarian arm of the Fosun Group and is a "5A Social Organization". Adhering to Fosun's values of "Self-improvement, Teamwork, Performance and Contribution to Society", Fosun Foundation insists on serving the society, the people and the nation. The coverage of the foundation includes disaster relief, rural revitalization, healthcare, poverty alleviation, youth entrepreneurship, education, and culture & art, etc., serving many countries and regions around the world

RURAL DOCTORS PROGRAM

As of the end of December 2023, the program has covered 78 counties in 16 provinces, municipalities, and autonomous regions, sent a total of 371 staff members to assist the counties, served approx. 25,000 rural doctors and benefited 3 million grassroots families

ASSIST AFRICA IN FIGHTING AGAINST MALARIA

As of December 2023, Fosun Pharma supplied over 340 million vials of artesunate for injection to the international market, which benefited over 68 million patients with severe malaria

EMERGING VISIONARIES

Over the past ten years, more than 6,500 Chinese middle school students have applied to the program, and two Charity Ambassadors selected each year are invited to represent China in the United States to receive awards and participate in global exchanges

TAI CHI ANTI-PARKINSON'S DISEASE TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

The scientific research findings of Tai Chi as an adjuvant therapy for chronic diseases were published in international authoritative journals.

As of the end of 2023, Fosun Foundation has organized 3,514 hours of offline and 1,062.5 hours of online charitable Tai Chi classes to 563 patients with Parkinson's disease

PROTECHTING GLOBAL YOUTH START-UP ACCELERATION PROGRAM

Received nearly 900 applications from 40+ countries and regions since 2016; won 3 international awards in recognition of its corporate social responsibility; 33 closely cooperated start-up projects and 5 companies signed commercial contracts

FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) is a non-profit organization launched and supported by the Fosun Group and Fosun Foundation. Its programs are characterized by contemporary, international, and highly interactive artworks. It has held a total of 28 art exhibitions and has attracted more than 1.75 million visitors since 2016

EMERGENCY RELIEF

In January 2023, "A Healthy Winter Action" was launched to donate Azvudine Tablets to rural areas in central and western China. In February 2023, Fosun Foundation joined hands with Tom Tailor and Fosun Trade to make donation to Turkey. In July 2023, it joined hands with many caring artists and companies to assist in flood relief in the northeastern region of Beijing, Tianjin and Hebei. In December 2023, it joined hands with caring artists and companies to assist in earthquake relief in Qinghai, Gansu.

FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) was opened in June 2022. The Taicang Special project of Fosun Foundation (Shanghai) was established in November 2023. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as Liberty 28 in New York to promote global cultural and artistic exchanges

28 art exhibitions

1.75 million+ visitors

Committed to presenting international and Chinese contemporary art exhibitions and special exhibitions with rich content, including "Tadao Ando: Endeavors", "Yayoi Kusama: All About Love Speaks Forever", "Liu Jianhua: Metaphysical Objects", etc.


550+ public education campaigns

45,000+ participants
in public education campaigns

Insist on organizing high-quality public education campaigns to help the public understand art and promote active participation in art-related events

400+ Fosun Foundation (Shanghai) Night and Aesthetic Journey

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends




RURAL DOCTORS PROGRAM

Delivering hope to impoverished people in rural areas

The Rural Doctors Program is one of the key initiatives to promote social development. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation, etc., initiated the Rural Doctors Poverty Alleviation Program ("Rural Doctors Program") to empower millions of rural doctors who are working in the frontlines, thereby accelerating the realization of Healthy China

371	78
On-site workers	Counties covered across the country
25,000	3 million
Rural doctors served	Grassroots families benefited

- In September 2021, the Rural Doctors Program was awarded the "China Charity Award"
- In December 2022, the Rural Doctors Program was awarded the "Shanghai Charity Award"
- The micro-documentary, *For Their Clear Sky* won Best Film on "Rural Revitalization" in the short film category at the 13th Beijing International Film Festival



CONTRIBUTING A CHINESE SOLUTION TO BUILD A "MALARIA-FREE WORLD"

340 million+

The number of vials of artesunate for injection (60mg) that Fosun Pharma supplied to the global market as of December 2023

68 million+

The number of patients with severe malaria that Artesun® (artesunate for injection) has saved



258 million

The number of children in African benefited from an intervention known as seasonal malaria chemoprevention (SMC)

Second-generation artesunate for injection, Artesun®

Artesun®, the second-generation artesunate for injection self-developed by Fosun Pharma has become the first artesunate injectable presented with a single solvent system that received the WHO PQ, which will further enhance the accessibility of innovative antimalarial drugs and save more lives

"We will join forces and work with anti-malaria experts as well as other parties to continue to carry out malaria education projects for the public in high malaria transmission African countries and raise the awareness of malaria prevention among doctors and patients. We will also actively participate in public health improvement and make steady efforts to build a malaria-free world."

—— Guo Guangchang

